• Improving Data Standardization in Neuroscience Research

    Bio-IT World | Recent advances in the commercialization of neuroscience data acquisition technology have enabled a quickly growing collection of massive brain activity and behavioral datasets. Within the data lie exciting promises of solving how the brain generates behavior, and how it might be better healed when diseased or disturbed. But interpreting these large, high-dimensional datasets isn’t easy. We need modern, collaborative solutions that help scale data management, analysis, and knowledge sharing.

    Jun 17, 2022

  • Moving Data for Clinical Trials: Standards, Systems to Link EHRs with EDC

    Bio-IT World | “Thirty to 40% of clinical trial costs are associated with actually just the manual retyping of [EHR] data [into the clinical trial system], and it leads to reporting delays and a number of other inefficiencies,” Adam Asare, chief data officer at the Quantum Leap Healthcare Collaborative/UCSF, told the Bio-IT World Conference & Expo audience last month. Asare shared a solution to that problem: a collaboration with OpenClinica that won the team a Bio-IT World Innovative Practices Award.

    Jun 16, 2022

  • Tag Technology Helps Drugmakers Assess If ‘The Juice Is Worth The Squeeze’

    Bio-IT World | While the field of targeted protein degradation (TPD) continues its rapid expansion, with multiple TPD drugs now in clinical trials, researchers in Australia are jumping in at an earlier stage with “tag technology” to ensure the disease protein is worth designing a drug against in the first place. Their work—an extension of other tag-targeting protein degradation technologies—gives researchers the wherewithal to ask if, “the juice is worth the squeeze,” according to Rebecca Feltham, Ph.D., laboratory head in the Ubiquitin Signalling Division of the Walter and Eliza Hall Institute.

    Jun 15, 2022

  • ‘Federated Analysis’ Helps Fill Genetic Risk Knowledge Gap On BRCA Genes

    Bio-IT World | A significantly heightened risk of breast cancer has two well-known culprits—mutations to the tumor suppressor genes BRCA1 and BRCA2—but more than 40% of the time they are black-box “variants of uncertain significance.” Using a new data-sharing innovation known as federated analysis, however, an international team of researchers has categorized 16 of these uncertain variants as benign or likely benign so their carriers may be able to have their clinical risk of disease managed properly and avoid the risk of invasive and irrevocable surgeries.

    Jun 14, 2022

  • Biotech Industry Leaders Give Advice to Earlier-Career Scientists

    Bio-IT World | Over the past two years, Stan Gloss, founding partner at BioTeam, has been sitting down with leaders in pharma and biotech for our Trends from the Trenches column and—more recently—the Trends from the Trenches podcast. They have been wide-ranging conversations covering everything from digital transformation at big pharma to All of Us and population genomics, data-driven cancer genomics to AI/ML models in drug discovery.

    Jun 9, 2022

  • Genetic Control Of Autoimmune Disease Mapped To Cellular Level

    Bio-IT World | The pioneering OneK1K study in Australia has identified an immune “fingerprint” of seven autoimmune disorders using single-cell RNA sequencing (scRNA-seq). The general framework, which combines the scRNA-seq data with genotype data to classify individual cells, can be applied to many different diseases.

    Jun 8, 2022

  • Building a Tech-Enabled Drug Discovery Pipeline at AstraZeneca

    Bio-IT World | Innovative Practices Award | AstraZeneca is using technology to speed and improve drug discovery at every step of the process, explained Anna Berg Asberg, global VP of R&D IT, last month in her presentation at the Bio-IT World Conference and Expo outlining AstraZeneca’s Bio-IT World Innovative Practices Award-winning project.

    Jun 7, 2022

  • The Role of AI in Precision Health Explored at Bio-IT World Conference

    Bio-IT World | At the Bio-IT World Conference & Expo last month, several sessions explored ways AI is transforming oncology diagnosis, research, and care delivery. Speakers from the National Cancer Institute, Tempus Labs, The Ohio State University, IQVIA, Pangaea Data, University of Illinois Cancer Center, Stable Solutions and more discussed how far we’ve come, and where our next challenges lie.

    Jun 7, 2022

  • Guardant and IQVIA Develop Precision Oncology Platform to Normalize Clinical Data

    Bio-IT World | Innovative Practices Award | Extracting high-quality data from clinical records can be time-consuming and costly, primarily when manual abstractors are tasked with mining complex, unstructured, and lengthy documents. That’s why the scientists at Guardant Health and Linguamatics, an IQVIA company, launched a real-world evidence database called GuardantINFORM. The platform was named one of the 2022 Bio-IT World Innovative Practices award winners.

    Jun 2, 2022

  • Chasing Digital Twins: Pilot Project Tackles Cancer Patient Twins in Neuro-Oncology

    Bio-IT World | At the Bio-IT World Conference & Expo last month, a team of researchers reported on their 12-week pilot effort to build cancer patient digital twins to aid in oncologist decision-making.

    Jun 1, 2022

  • Bio-IT Experts on Keeping Data Secure, Accessible for Research

    Bio-IT World | In a wide-ranging discussion on data security this month at the Bio-IT World Conference and Expo, panelists dug into how the data we have can be better positioned to inform research in the future—and what that means for both patients and researchers.

    May 31, 2022

  • Pharma-Genedata Collaboration Builds ROI-Rich Tool for Omics Data Exploration

    Bio-IT World | Innovative Practices Award | Merck KGaA, Darmstadt, began developing the X-OMICS platform in conjunction with Genedata, a Swiss software provider with 25 years’ worth of experience digitalizing biopharmaceutical research and development, in 2017. The platform went live in 2020 and over the past two years has saved millions of dollars, months of time, and launched a data culture revolution.

    May 31, 2022

  • Cloud-Based HIV Registry, Oxford Nanopore Catalogs Structural Variants, More

    Bio-IT World | Proscia launches an automated quality-control application that leverages artificial intelligence to improve drug development; an end-to-end software and data management package aids antibody discovery; ArisGlobal acquires BI’s analytic system; a data cloud is used for increased statistical analysis efficiency; new products from SCIEX and Dotmatics, and more.

    May 26, 2022

  • Follow the Money: Data Protection and Security, Precision Medicine Platform, More

    Bio-IT World| Funding for data protection and security platforms, autologous cell therapies, rapid DNA sequencing, and more.

    May 25, 2022

  • Multi-omics Analysis Sheds Light on Drivers of Alzheimer’s Disease, Other Neurodegeneration

    Bio-IT World | “I want to disabuse you of any illusion there exists black-box technologies where you can feed in data from multiple omics inputs and out comes interesting biology,” Shankar Subramaniam told the crowd in Boston earlier this month at the Bio-IT World Conference and Expo. “That’s a myth.”

    May 24, 2022

  • Kim Branson on Building Groundbreaking AI/ML GSK Models in Drug Discovery

    Bio-IT World | Dr. Kim Branson’s long-standing fascination with small molecule drug discovery and structural biology led to an established career in machine learning. After studying in Australia, Branson trained at Stanford and now works as the Senior Vice President and Global Head of AI/ML at GlaxoSmithKline (GSK). In the latest episode of Bio-IT World’s Trends from the Trenches podcast, Branson and host, Stan Gloss, discuss machine learning, human genetics, functional genomics, and how each predicts various aspects of health.

    May 24, 2022

  • Benchling Releases AlphaFold beta Integration

    Bio-IT World | Benchling launched its AlphaFold beta feature today, designed to overcome challenges of implementation, computing power, and resourcing to make for ease of experimentation and integration with AlphaFold on the Benchling platform.

    May 19, 2022

  • Patient Advocacy Groups Band Together To Further Rare Disease Research

    Bio-IT World | The fast-growing Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders (COMBINEDBrain) represents patient advocacy organizations for individuals with rare, neurodevelopmental diseases who are disadvantaged by the small number of affected individuals and scientific brainpower to lead the way.

    May 19, 2022

  • Dozens Of New Genetic Risk Factors For Alzheimer’s Disease Identified

    Bio-IT World | A meta-analysis of new and previous genome-wide association studies (GWAS) has identified 75 genetic risk factors for Alzheimer’s disease (AD), 42 of which weren’t previously implicated. The investigation confirms the importance of two pathological brain phenomena that are currently pursued therapeutic targets and strengthens the case for having microglial cells join the hit list, according to Jean-Charles Lambert, research director at Inserm (National Institute of Health and Medical Research) based in Lille, France.

    May 18, 2022

  • Expert Panel: Inclusion and Diversity in Life Sciences and Precision Medicine

    Bio-IT World | Bio-IT World Conference & Expo panelists discussed how diversity, equity, and inclusion are critical to the efficacy of precision medicine. Moderator Kevin Ileka, Bristol Myers Squibb Co., was joined by Adrian Coles, Bristol Myers Squibb Co.; Ari Berman, BioTeam Inc; Lori Lennon, Thinkubator Media; and Victoria Parker, NOBCChE.

    May 17, 2022